Acceleron Pharma price target raised to $65 from $35 at Piper Jaffray Piper Jaffray raised its price target for Acceleron Pharma shares to $65 ahead of the clinical data read-outs it expects to start in June. Piper expects share value to be driven by the company's clinical progress for dalantercept, as it sees blockbuster potential in multiple cancers. The firm reiterates an Overweight rating on Acceleron.
News For XLRN From The Last 14 Days
Check below for free stories on XLRN the last two weeks.
Piper Jaffray tech and biopharma analysts hold analyst/industry conference call Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.